Deodhar A

No ORCID on file · 1 paper in corpus · active 2012
2012
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.
Annals of the rheumatic diseases ·doi:10.1136/ard.2011.154799

ObjectiveTo assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis.MethodsAt baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous…